Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Clin Pharmacol Ther. 2021 Sep;110(3):794-802. doi: 10.1002/cpt.2241. Epub 2021 Apr 21.
We conducted the first human leukocyte antigen (HLA) allele and genome-wide association study to identify loci associated with hypersensitivity reactions exclusively to the PEGylated preparation of asparaginase (pegaspargase) in racially diverse cohorts of pediatric leukemia patients: St Jude Children's Research Hospital's Total XVI (TXVI, n = 598) and Children's Oncology Group AALL0232 (n = 2,472) and AALL0434 (n = 1,189). Germline DNA was genotyped using arrays. Genetic variants not genotyped directly were imputed. HLA alleles were imputed using SNP2HLA or inferred using BWAkit. Analyses between genetic variants and hypersensitivity were performed in each cohort first using cohort-specific covariates and then combined using meta-analyses. Nongenetic risk factors included fewer intrathecal injections (P = 2.7 × 10 in TXVI) and male sex (P = 0.025 in AALL0232). HLA alleles DQB102:02, DRB107:01, and DQA102:01 had the strongest associations with pegaspargase hypersensitivity (P < 5.0 × 10 ) in patients with primarily European ancestry (EA), with the three alleles associating in a single haplotype. The top allele HLA-DQB102:02 was tagged by HLA-DQB1 rs1694129 in EAs (r = 0.96) and less so in non-EAs. All single nucleotide polymorphisms associated with pegaspargase hypersensitivity reaching genome-wide significance in EAs were in class II HLA loci, and were partially replicated in non-EAs, as is true for other HLA associations. The rs9958628 variant, in ARHGAP28 (previously linked to immune response in children) had the strongest genetic association (P = 8.9 × 10 ) in non-EAs. The HLA-DQB102:02-DRB107:01-DQA1*02:01 associated with hypersensitivity reactions to pegaspargase is the same haplotype associated with reactions to non-PEGylated asparaginase, even though the antigens differ between the two preparations.
我们进行了首次人类白细胞抗原 (HLA) 等位基因和全基因组关联研究,以鉴定与聚乙二醇化制剂 (pegaspargase) asparaginase 过敏反应相关的基因座,研究对象为来自不同种族的儿科白血病患者:圣裘德儿童研究医院的 Total XVI (TXVI,n=598)、儿童肿瘤组 AALL0232 (n=2472) 和 AALL0434 (n=1189)。使用基因芯片对胚系 DNA 进行基因分型。未直接基因分型的遗传变异使用 imputation 进行推断。使用 SNP2HLA 或 BWAkit 推断 HLA 等位基因。首先在每个队列中使用队列特异性协变量进行遗传变异与过敏反应之间的分析,然后使用荟萃分析进行合并。非遗传风险因素包括鞘内注射次数较少(在 TXVI 中为 P=2.7×10)和男性(在 AALL0232 中为 P=0.025)。在主要为欧洲血统 (EA) 的患者中,HLA 等位基因 DQB102:02、DRB107:01 和 DQA102:01 与 pegaspargase 过敏反应具有最强的关联(P<5.0×10),这三个等位基因在单个单倍型中关联。在 EA 中,与 pegaspargase 过敏反应相关的顶级 HLA-DQB102:02 等位基因由 HLA-DQB1 rs1694129 标记(r=0.96),而非 EA 中则较少。在 EA 中达到全基因组显著水平的与 pegaspargase 过敏反应相关的所有单核苷酸多态性均位于 II 类 HLA 基因座,在非 EA 中也得到部分复制,与其他 HLA 关联相同。在非 EA 中,ARHGAP28 中的 rs9958628 变异(先前与儿童免疫反应相关)与 pegaspargase 过敏反应的遗传关联最强(P=8.9×10)。与 peg 化制剂 asparaginase 过敏反应相关的 HLA-DQB102:02-DRB107:01-DQA1*02:01 与与非 peg 化 asparaginase 过敏反应相关的相同单倍型,尽管两种制剂的抗原不同。